BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 17051861)

  • 1. [How I treat and manage erectile dysfunction in diabetics].
    Buvat J
    Journ Annu Diabetol Hotel Dieu; 2006; ():185-203. PubMed ID: 17051861
    [No Abstract]   [Full Text] [Related]  

  • 2. Emergence and success of PDE5 inhibitors as effective therapy for erectile dysfunction.
    Manganiello V
    Int J Impot Res; 2004 Jun; 16 Suppl 1():S1-3. PubMed ID: 15224126
    [No Abstract]   [Full Text] [Related]  

  • 3. Optimisation of PDE5 inhibitor therapy in men with erectile dysfunction: converting "non-responders" into "responders".
    Eardley I
    Eur Urol; 2006 Jul; 50(1):31-3. PubMed ID: 16517052
    [No Abstract]   [Full Text] [Related]  

  • 4. Cyclic GMP and phosphodiesterase 5 inhibitor therapies: what's on the horizon?
    Lincoln TM
    Mol Pharmacol; 2004 Jul; 66(1):11-3. PubMed ID: 15213291
    [No Abstract]   [Full Text] [Related]  

  • 5. Salvage techniques for phosphodiesterase 5 inhibitor therapy: purposeful but how much?
    Burnett AL
    Eur Urol; 2006 Jul; 50(1):29-30. PubMed ID: 16567036
    [No Abstract]   [Full Text] [Related]  

  • 6. Chapter 1: The management of erectile dysfunction: an AUA update.
    Montague DK; Jarow JP; Broderick GA; Dmochowski RR; Heaton JP; Lue TF; Milbank AJ; Nehra A; Sharlip ID;
    J Urol; 2005 Jul; 174(1):230-9. PubMed ID: 15947645
    [No Abstract]   [Full Text] [Related]  

  • 7. First-line therapies for erectile dysfunction.
    Ensign C
    JAAPA; 2001 Oct; 14(10):17-20. PubMed ID: 11715672
    [No Abstract]   [Full Text] [Related]  

  • 8. Rationale for androgens and erectile dysfunction in 2006.
    Roumeguère T
    Eur Urol; 2006 Nov; 50(5):898-900. PubMed ID: 16893603
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficacy of PDE-5-inhibitors for erectile dysfunction. A comparative meta-analysis of fixed-dose regimen randomized controlled trials administering the International Index of Erectile Function in broad-spectrum populations.
    Rosen RC; Shaw JW
    Int J Impot Res; 2006; 18(6):570-1; author reply 572-3. PubMed ID: 17075585
    [No Abstract]   [Full Text] [Related]  

  • 10. Review of time of onset and duration of clinical efficacy of phosphodiesterase type 5 inhibitors in treatment of erectile dysfunction.
    Shabsigh R; Seftel AD; Rosen RC; Porst H; Ahuja S; Deeley MC; Garcia CS; Giuliano F
    Urology; 2006 Oct; 68(4):689-96. PubMed ID: 17070333
    [No Abstract]   [Full Text] [Related]  

  • 11. SAR development of polycyclic guanine derivatives targeted to the discovery of a selective PDE5 inhibitor for treatment of erectile dysfunction.
    Pissarnitski DA; Asberom T; Boyle CD; Chackalamannil S; Chintala M; Clader JW; Greenlee WJ; Hu Y; Kurowski S; Myers J; Palamanda J; Stamford AW; Vemulapalli S; Wang Y; Wang P; Wu P; Xu R
    Bioorg Med Chem Lett; 2004 Mar; 14(5):1291-4. PubMed ID: 14980684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation and diagnostic testing of erectile dysfunction in the era of phosphodiesterase type 5 inhibitors.
    Jacobsohn K; Wang R
    Asian J Androl; 2007 Jan; 9(1):3-7. PubMed ID: 17187154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. This paper continues Professor Adaikan's distinguished involvement in classical pharmacologic research of erectile physiology.
    Pickard R
    Eur Urol; 2007 Jul; 52(1):259-60. PubMed ID: 17616089
    [No Abstract]   [Full Text] [Related]  

  • 14. Quinolines as extremely potent and selective PDE5 inhibitors as potential agents for treatment of erectile dysfunction.
    Bi Y; Stoy P; Adam L; He B; Krupinski J; Normandin D; Pongrac R; Seliger L; Watson A; Macor JE
    Bioorg Med Chem Lett; 2004 Mar; 14(6):1577-80. PubMed ID: 15006407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The treatment options broaden. New chances for libido].
    Einecke U
    MMW Fortschr Med; 2002 May; 144(19):4-6. PubMed ID: 12116552
    [No Abstract]   [Full Text] [Related]  

  • 16. [Chronic treatment with PDE-5 inhibitors is there anything more than treating erectile dysfunction?].
    Vela Navarrete R; García Cardoso JV; López Farre A; Quesada Romero P; Pardo Montero M
    Actas Urol Esp; 2007 Mar; 31(3):179-84. PubMed ID: 17658146
    [No Abstract]   [Full Text] [Related]  

  • 17. Assessment and management of erectile dysfunction.
    Webb V; Holmes A
    Nurs Times; 1999 Jan 13-19; 95(2):48-9. PubMed ID: 10067601
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical evaluation of erectile dysfunction in the era of PDE-5 inhibitors.
    Lobo JR; Nehra A
    Urol Clin North Am; 2005 Nov; 32(4):447-55, vi. PubMed ID: 16291036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphodiesterase type 5 inhibithors in older males.
    Frajese GV; Pozzi F
    J Endocrinol Invest; 2005; 28(11 Suppl Proceedings):112-5. PubMed ID: 16760638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erectile dysfunction drugs and nonarteritic anterior ischemic optic neuropathy.
    Lee AG; Newman NJ
    Am J Ophthalmol; 2005 Oct; 140(4):707-8. PubMed ID: 16226524
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.